Expression Analysis, Inc., a provider of genomic services for clinical trials and research, has entered into a partnership with Sunderland-based Complement Genomics Ltd. to offer its genomic services to the UK market. By partnering with an established company, Expression Analysis will gain access to clients beyond its primary market in the US.

The Geneblitz unit offers molecular services to pharmaceutical companies, governmental agencies, universities and research institutes. The partnership will give Expression Analysis access to these clients and will allow both companies to expand their service offerings. 

"The partnership with Geneblitz provides us an established presence in the United Kingdom, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms," stated Steve McPhail, President and CEO of Expression Analysis. "Geneblitz will focus its efforts on Genome-Wide Association studies which have become an increasingly larger part of our business," continued McPhail.